推荐产品
等级
pharmaceutical primary standard
API类
misoprostol
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
−20°C
SMILES字符串
CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
InChI
1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
InChI key
OJLOPKGSLYJEMD-URPKTTJQSA-N
基因信息
human ... PTGER3(5733)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Misoprostol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
PGE 1 类似物前体药物，迅速去酯化为活性“米索前列醇酸”。广泛的治疗作用，包括预防 NSAID 诱导的胃溃疡、调节免疫级联反应、抑制血小板活化因子（PAF）、治疗乙醇和扑热息痛诱导的肝毒性和肝炎以及刺激损伤后的软骨修复。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral - Repr. 1B
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
C W Ho et al.
Alimentary pharmacology & therapeutics, 37(8), 819-824 (2013-02-26)
Poor adherence to gastroprotective agents (GPAs) is common among users of nonsteroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (ASA). There are little data on the utilization of GPAs among NSAID and ASA users complicated by ulcer bleeding. To study the
Jeffrey Michael Smith et al.
BMC pregnancy and childbirth, 13, 44-44 (2013-02-21)
Hemorrhage continues to be a leading cause of maternal death in developing countries. The 2012 World Health Organization guidelines for the prevention and management of postpartum hemorrhage (PPH) recommend oral administration of misoprostol by community health workers (CHWs). However, there
Heleen J van Beekhuizen et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 122(3), 234-237 (2013-06-25)
To evaluate the efficacy and safety of misoprostol among patients with retained placenta in a low-resource setting. A prospective, multicenter, randomized, double-blind, placebo-controlled trial was carried out in Tanzania between April 2008 and November 2011. It included patients who delivered
Deborah Bartz et al.
Obstetrics and gynecology, 122(1), 57-63 (2013-06-08)
To compare the efficacy and acceptability of buccal misoprostol or a synthetic osmotic cervical dilator for cervical preparation before same-day late first-trimester and early second-trimester surgical abortion. In this randomized, double-blind trial, we compared 400 micrograms of buccal misoprostol with
Amanda Selk et al.
Obstetrics and gynecology, 118(4), 941-949 (2011-09-22)
To estimate the benefits and harms of misoprostol use for cervical dilation in patients undergoing operative hysteroscopy. We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (from inception to February 2011). We also searched trial registries, other
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门